The global scientific community has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
This change marks a fundamental shift in how medical professionals describe a condition that affects one in eight women worldwide [1]. By retiring the term "cysts," the new name aligns the clinical title with the actual hormonal and metabolic drivers of the disorder.
The announcement was made in New Delhi, India, coinciding with World Menstrual Hygiene Day [2]. Physicians and researchers devoted to hormone-related conditions reached the consensus to eliminate terminology that they said is misleading.
For years, the reference to "cysts" in the original name caused confusion regarding the nature of the condition. The new designation, PMOS, emphasizes that the disorder is not merely an ovarian issue but a systemic endocrine and metabolic challenge [2].
According to reported data, the condition affects approximately 170 million women globally [2]. The transition to the new terminology is intended to improve diagnostic accuracy and patient understanding of the root causes of their symptoms.
Medical experts said the update reflects a deeper understanding of the polyendocrine nature of the syndrome. By focusing on metabolic and endocrine dysfunction, the scientific community aims to move away from the inaccurate focus on ovarian cysts as the primary defining characteristic [2].
“The shift to Polyendocrine Metabolic Ovarian Syndrome removes misleading references to cysts.”
The transition from PCOS to PMOS represents a pivot toward a holistic, systemic understanding of the disorder. By removing the word 'cystic,' the medical community is acknowledging that the condition is a complex metabolic and endocrine failure rather than a localized ovarian problem. This may lead to more integrated treatment approaches that prioritize metabolic health over simple symptom management of the ovaries.
